{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T18:31:43Z","timestamp":1788201103430,"version":"build-2803163510"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"16","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Chimeric antigen receptor T (CAR-T) cells have been demonstrated to be an effective treatment for relapsed B-cell acute lymphoblastic leukemia (B-ALL) following allogeneic hematopoietic stem cell transplantation (allo-HSCT). T cells for CAR-T therapy can be derived from the peripheral blood (recipient) of the patient or donor. Despite having identical genomes, the different maturation environments of these T cells can lead to functional differences. This study aimed to compare the clinical outcomes of CAR-T cells derived from these two sources.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This multicenter, retrospective cohort study collected clinical data from 36 patients who experienced B-ALL relapse after allo-HSCT and received CD19 CAR-T cell therapy between January 2016 and October 2023 across seven centers. The primary endpoint was complete remission (CR)\/CR with an incomplete hematologic recovery (CRi) rate at 28 days post-CAR-T cell infusion. Secondary endpoints included the 2-year overall survival (OS) rate, 2-year event-free survival (EFS) rate, incidence of graft-versus-host disease (GVHD), cytokine release syndrome (CRS), and CAR-T cell-related encephalopathy syndrome (CRES).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A retrospective analysis was performed on 36 patients: 12 in the recipient group and 24 in the donor group. The recipient and donor groups showed no statistically significant differences in CR\/CRi rates (83.3%\n                      <jats:italic toggle=\"yes\">vs.<\/jats:italic>\n                      100.0%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.105), 2-year EFS rates (50.8%\n                      <jats:italic toggle=\"yes\">vs.<\/jats:italic>\n                      51.6%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.617), or 2-year OS rates (49.5%\n                      <jats:italic toggle=\"yes\">vs.<\/jats:italic>\n                      63.6%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.215). In addition, the incidences of GVHD, CRS, and CRES did not significantly differ between the two groups. Further analysis within the donor group revealed 12 matched sibling donors (MSDs) and 12 haploidentical donors (HIDs). The 2-year EFS rate was statistically significantly greater in the HID group than in the MSD group (75.0%\n                      <jats:italic toggle=\"yes\">vs.<\/jats:italic>\n                      30.7%,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.043), whereas no significant differences were observed in the CR\/CRi rates, 2-year OS, or the incidence of GVHD, CRS, and CRES between these subgroups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Both recipient-derived and donor-derived CD19 CAR-T cell therapies are effective treatment options for B-ALL relapsed post-allo-HSCT patients. HID-derived CAR-T cells offer a longer EFS and may be considered the optimal choice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration:<\/jats:title>\n                    <jats:p>Chinese Clinical Trial Registry, No. ChiCTR2400085297.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/cm9.0000000000003855","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T11:00:19Z","timestamp":1765537219000},"page":"2479-2486","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Recipient-derived vs. donor-derived CAR-T-cell therapy in relapsed B-cell acute lymphoblastic leukemia patients after transplantation: A multi-center retrospective study"],"prefix":"10.1097","volume":"139","author":[{"given":"Lichao","family":"Liu","sequence":"first","affiliation":[{"name":"Medical Center of Hematology, Institute of Science Innovation for Blood Ecology and Intelligent Cells, Xinqiao Hospital of Army Medical University, Chongqing 400037, China"},{"name":"Chongqing Key Laboratory of Hematology and Microenvironment, Chongqing 400037, China"},{"name":"State Key Laboratory of Trauma and Chemical Poisoning, Army Medical University, Chongqing 400037, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxian","family":"Hu","sequence":"additional","affiliation":[{"name":"Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruihao","family":"Huang","sequence":"additional","affiliation":[{"name":"Medical Center of Hematology, Institute of Science Innovation for Blood Ecology and Intelligent Cells, Xinqiao Hospital of Army Medical University, Chongqing 400037, China"},{"name":"Chongqing Key Laboratory of Hematology and Microenvironment, Chongqing 400037, China"},{"name":"State Key Laboratory of Trauma and Chemical Poisoning, Army Medical University, Chongqing 400037, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhua","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong 510280, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanfang","family":"Tu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong 510280, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shangjun","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Yi","sequence":"additional","affiliation":[{"name":"Department of Hematology, The General Hospital of Western Theater Command, People\u2019s Liberation Army, Chengdu, Sichuan 610083, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiuying","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Hematology, Shaanxi Provincial People\u2019s Hospital, Xi\u2019an, Shaanxi 710068, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Haematology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan 450008, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Tan","sequence":"additional","affiliation":[{"name":"Medical Center of Hematology, Institute of Science Innovation for Blood Ecology and Intelligent Cells, Xinqiao Hospital of Army Medical University, Chongqing 400037, China"},{"name":"Chongqing Key Laboratory of Hematology and Microenvironment, Chongqing 400037, China"},{"name":"State Key Laboratory of Trauma and Chemical Poisoning, Army Medical University, Chongqing 400037, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Medical Center of Hematology, Institute of Science Innovation for Blood Ecology and Intelligent Cells, Xinqiao Hospital of Army Medical University, Chongqing 400037, China"},{"name":"Chongqing Key Laboratory of Hematology and Microenvironment, Chongqing 400037, China"},{"name":"State Key Laboratory of Trauma and Chemical Poisoning, Army Medical University, Chongqing 400037, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqi","family":"Wang","sequence":"additional","affiliation":[{"name":"Medical Center of Hematology, Institute of Science Innovation for Blood Ecology and Intelligent Cells, Xinqiao Hospital of Army Medical University, Chongqing 400037, China"},{"name":"Chongqing Key Laboratory of Hematology and Microenvironment, Chongqing 400037, China"},{"name":"State Key Laboratory of Trauma and Chemical Poisoning, Army Medical University, Chongqing 400037, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Medical Center of Hematology, Institute of Science Innovation for Blood Ecology and Intelligent Cells, Xinqiao Hospital of Army Medical University, Chongqing 400037, China"},{"name":"Chongqing Key Laboratory of Hematology and Microenvironment, Chongqing 400037, China"},{"name":"State Key Laboratory of Trauma and Chemical Poisoning, Army Medical University, Chongqing 400037, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"key":"R1-20260820","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1038\/leu.2011.351","article-title":"Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT","volume":"26","author":"Spyridonidis","year":"2012","journal-title":"Leukemia"},{"key":"R2-20260820","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1200\/JCO.22.00642","article-title":"Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia in the ELIANA trial","volume":"41","author":"Laetsch","year":"2023","journal-title":"J Clin Oncol"},{"key":"R3-20260820","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1097\/CM9.0000000000002549","article-title":"Clinical development of chimeric antigen receptor-T cell therapy for hematological malignancies","volume":"136","author":"Yang","year":"2023","journal-title":"Chin Med J"},{"key":"R4-20260820","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005701","article-title":"Safety and efficacy of autologous and allogeneic humanized CD19-targeted CAR-T cell therapy for patients with relapsed\/refractory B-ALL","volume":"11","author":"Song","year":"2023","journal-title":"J Immunother Cancer"},{"key":"R5-20260820","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1007\/s13577-023-00934-2","article-title":"Donor-derived CAR-T therapy improves the survival of relapsed B-ALL after allogeneic transplantation compared with donor lymphocyte infusion","volume":"36","author":"Liang","year":"2023","journal-title":"Hum Cell"},{"key":"R6-20260820","doi-asserted-by":"crossref","DOI":"10.1177\/09636897231158155","article-title":"Donor hematopoietic stem cell\/lymphocyte maintenance treatment after CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia relapse following stem cell transplant","volume":"32","author":"Li","year":"2023","journal-title":"Cell Transplant"},{"key":"R7-20260820","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41408-022-00688-4","article-title":"Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia","volume":"12","author":"Zhang","year":"2022","journal-title":"Blood cancer journal"},{"key":"R8-20260820","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/s41375-021-01351-w","article-title":"Preemptive donor-derived anti-CD19 CAR T-cell infusion showed a promising anti-leukemia effect against relapse in MRD-positive B-ALL after allogeneic hematopoietic stem cell transplantation","volume":"36","author":"Zhao","year":"2022","journal-title":"Leukemia"},{"key":"R9-20260820","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217264","article-title":"Consensus on the monitoring, treatment, and prevention of leukaemia relapse after allogeneic haematopoietic stem cell transplantation in China: 2024 update","volume":"605","author":"Wang","year":"2024","journal-title":"Cancer Lett"},{"key":"R10-20260820","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/s41571-021-00485-1","article-title":"Will allogeneic CAR T cells for CD19(+) malignancies take autologous CAR T cells \u2018off the shelf\u2019?","volume":"18","author":"DiNofia","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"R11-20260820","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1038\/s41375-020-01056-6","article-title":"Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant","volume":"35","author":"Zhang","year":"2021","journal-title":"Leukemia"},{"key":"R12-20260820","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s11596-023-2746-1","article-title":"Donor-derived CD19 CAR-T cells versus chemotherapy plus donor lymphocyte infusion for treatment of recurrent CD19-positive B-ALL after allogeneic hematopoietic stem cell transplantation","volume":"43","author":"Tan","year":"2023","journal-title":"Curr Med Sci"},{"key":"R13-20260820","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/CJI.0000000000000233","article-title":"Donor-derived CAR-T cells serve as a reduced-intensity conditioning regimen for haploidentical stem cell transplantation in treatment of relapsed\/refractory acute lymphoblastic leukemia: Case report and review of the literature","volume":"41","author":"Zhang","year":"2018","journal-title":"J Immunother"},{"key":"R14-20260820","first-page":"417","article-title":"Chinese guideline for diagnosis and treatment of adult acute lymphoblastic leukemia (2024) (in Chinese)","volume":"45","year":"2024","journal-title":"Chin J Hematol"},{"key":"R15-20260820","doi-asserted-by":"crossref","first-page":"3996","DOI":"10.1182\/blood-2015-03-580027","article-title":"Minimal residual disease diagnostics in acute lymphoblastic leukemia: Need for sensitive, fast, and standardized technologies","volume":"125","author":"van Dongen","year":"2015","journal-title":"Blood"},{"key":"R16-20260820","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"R17-20260820","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1038\/s41409-018-0204-7","article-title":"EBMT-NIH-CIBMTR Task Force position statement on standardized terminology and guidance for graft-versus-host disease assessment","volume":"53","author":"Schoemans","year":"2018","journal-title":"Bone Marrow Transplant"},{"key":"R18-20260820","first-page":"265","article-title":"Chinese consensus on the diagnosis and management of chronic graft-versus-host disease (in Chinese)","volume":"42","year":"2021","journal-title":"Chin J Hematol"},{"key":"R19-20260820","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/nm.4258","article-title":"Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity","volume":"23","author":"Ghosh","year":"2017","journal-title":"Nat Med"},{"key":"R20-20260820","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1053\/j.seminhematol.2018.07.005","article-title":"Is human leukocyte antigen-matched sibling donor transplant always better than haploidentical allograft?","volume":"56","author":"Chang","year":"2019","journal-title":"Semin Hematol"},{"key":"R21-20260820","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/d41573-023-00140-7","article-title":"The next-generation CAR-T therapy landscape","volume":"22","author":"Verma","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"R22-20260820","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"key":"R23-20260820","first-page":"383","article-title":"Allogeneic donor-derived CD19 CAR-T therapy of relapsed B-cell acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation (in Chinese)","volume":"42","author":"Ma","year":"2021","journal-title":"Chin J Hematol"},{"key":"R24-20260820","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2015.64.5929","article-title":"Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease","volume":"34","author":"Brudno","year":"2016","journal-title":"J Clin Oncol"},{"key":"R25-20260820","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2217\/imt-2016-0127","article-title":"Donor origin CAR T cells: graft versus malignancy effect without GVHD, a systematic review","volume":"9","author":"Anwer","year":"2017","journal-title":"Immunotherapy"},{"key":"R26-20260820","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1038\/s41409-018-0403-2","article-title":"A retrospective comparison of allogenic and autologous chimeric antigen receptor T cell therapy targeting CD19 in patients with relapsed\/refractory acute lymphoblastic leukemia","volume":"54","author":"Hu","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"R27-20260820","first-page":"318","article-title":"CAR-T therapy followed by allo-HSCT for patients with B-cell acute lymphoblastic leukemia relapsing after the first hematopoietic stem cell transplantation (in Chinese)","volume":"42","author":"Cao","year":"2021","journal-title":"Chin J Hematol"},{"key":"R28-20260820","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215721","article-title":"Unity brings strength: Combination of CAR-T cell therapy and HSCT","volume":"549","author":"Huang","year":"2022","journal-title":"Cancer Lett"},{"key":"R29-20260820","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1001\/jama.2024.1011","article-title":"FDA adds boxed warning to CAR T-Cell therapies, but says benefits outweigh risks of secondary cancers","volume":"331","author":"Suran","year":"2024","journal-title":"JAMA"},{"key":"R30-20260820","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMp2400209","article-title":"Secondary cancers after chimeric antigen receptor T-cell therapy","volume":"390","author":"Verdun","year":"2024","journal-title":"N Engl J Med"},{"key":"R31-20260820","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217083","article-title":"The underlying mechanism of chimeric antigen receptor (CAR)-T cell therapy triggering secondary T-cell cancers: Mystery of the sphinx?","volume":"597","author":"Zhou","year":"2024","journal-title":"Cancer Lett"},{"key":"R32-20260820","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1038\/s41409-021-01431-6","article-title":"Hematopoietic stem cell transplantation activity in China 2019: A report from the Chinese blood and marrow transplantation registry group","volume":"56","author":"Xu","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"R33-20260820","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13045-020-00910-5","article-title":"Recent advances in CAR-T cell engineering","volume":"13","author":"Huang","year":"2020","journal-title":"J Hematol Oncol"},{"key":"R34-20260820","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s13045-021-01209-9","article-title":"Born to survive: How cancer cells resist CAR T cell therapy","volume":"14","author":"Lemoine","year":"2021","journal-title":"J Hematol Oncol"},{"key":"R35-20260820","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1097\/CM9.0000000000003558","article-title":"Exploration and practice: New integration of cellular therapy and hematopoietic stem cell transplantation","volume":"138","author":"Huang","year":"2025","journal-title":"Chin Med J"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CM9.0000000000003855","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T04:01:33Z","timestamp":1787198493000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/CM9.0000000000003855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":35,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000003855","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,12]]},"assertion":[{"value":"2025-08-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}}]}}